rss twitter facebook


RA News

JAK Inhibitor Upadacitinib Shows Promise in Hard To Treat Individuals with Rheumatoid Arthritis

Upadacitinib is a once daily oral medicine belongs to a new class of oral medicines called janus kinase or JAK inhibitors.  Janus kinases are enzymes that play a role in inflammation and RA.  JAK inhibitors block the activity of these enzymes leading to a reduction in inflammation and are showing…

Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis

Both men and women with rheumatoid arthritis (RA) have a higher risk of heart attack than the general population, possibly due to the inflammation associated with RA.  In fact Acute Coronary Syndrome (ACS) is one of the major causes of morbidity and mortality in RA. In addition, when compared with…

Obesity- More Than a Weight Problem for Ankylosing Spondylitis (AS) and Other Rheumatic Conditions

Obesity is known to have detrimental effects on the musculoskeletal system because of the added strain on joint structures.  Another detrimental effect may be the blunting of a therapeutic response to a therapy. It has previously been reported that decreasing weight in psoriatic arthritis results in an improved responses to…

Withdrawal of TNF Inhibitors Fails in Most RA Patients

TNF inhibitors are biologic drugs that are commonly used in the treatment of rheumatoid arthritis (RA) and certain other autoimmune conditions. These drugs include Enbrel® (etanercept), Remicade® (infliximab), Humira® (adalimumab), Cimzia® (certolizumab), and Simponi® (golimumab). Many patients wonder how long they need to remain on therapy to control symptoms of…

Orencia Approved for Use in Psoriatic Arthritis

The U.S. Food and Drug Administration (FDA) has approved ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis (PsA). Approval is for both intravenous and subcutaneous (SC) injection formulations. Psoriatic arthritis is a condition that stems from psoriasis, an autoimmune disease in which the body’s immune system attacks…

Rituxan May Improve Rheumatoid Lung Disease

A single-center clinical trial with 10-year follow-up study of rheumatoid arthritis (RA) shows that treatment with Rituxan® (rituximab) in patients with RA-related interstitial lung disease (RA-ILD) may halt disease progression in the lungs. Rheumatoid arthritis is a chronic inflammatory disease that causes pain, stiffness, swelling, and limitation in the motion…

Managing Inflammatory Arthritis From Checkpoint Inhibitors

Inflammatory arthritis is a newly recognized side effect associated with immune checkpoint blockade, an increasingly used treatment for a number of cancers. According to Johns Hopkins doctors who submitted the report, immune checkpoint inhibitor-induced inflammatory arthritis is underappreciated and may be clinically severe, rapidly destructive, disabling, and affect a patient's…

Do NSAIDs Increase the Risk of Heart Attacks?

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed class of medicines used around the world, and are widely used by individuals with arthritis, and back pain.  Starting with the development of aspirin from the active agent found in willow bark (salicylic acid) NSAIDs have offered humans the ability to…

NOR-SWITCH Study Validates Biosimilar Use in Rheumatoid Arthritis

Results of the NOR-SWITCH study – a clinical trial performed in Norway was designed to assess the effectiveness and safety of transitioning from the originator medication Remicade (infliximab) to the less expensive biosimilar medication (Remsima/Inflectra) in the treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic…

The US Food and Drug Administration (FDA) has Approved Kevzara an IL-6 Inhibitor for the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA) affects an estimated 1.3 million adults in the United States.1 The condition can have a profound effect on many aspects of daily life, and is often poorly understood by those who do not have direct experience it. The good news is that important advances have been made…

Sign up for TheRAConnection Newsletter to receive the latest news, useful tips, and feature articles.

Click here to view the RAConnection past newsletters